mRNA Cancer Vaccine Shows Promise in Phase 3 Melanoma Trial
A personalized mRNA-based cancer vaccine developed by Moderna and Merck has shown promising results in a Phase 3 clinical trial for melanoma, according to initial reports from the companies.
The vaccine leverages messenger RNA technology similar to that used in COVID-19 vaccines, but is personalized to each patient. It works by targeting neoantigens—unique mutations present on an individual's cancer cells—to train the immune system to recognize and attack the tumor.
In the trial, the vaccine reportedly thwarted the cancer's return and spread in patients with melanoma, suggesting it could become a new option for preventing recurrence in this aggressive skin cancer.
This marks a significant milestone in the development of personalized cancer immunotherapies, which aim to harness the body's own immune system to fight cancer more precisely than traditional treatments.